Jason Ruth, PhD, is the CDCN’s Chief Scientific Officer. He is also a Senior Associate at 5AM Ventures, where he helps create and invest in early stage companies developing medicines for patients with unmet needs. He is an observer on the Board of Directors for several companies developing medicines for rare diseases, including Cabaletta Bio, Expansion Therapeutics, Vor Biopharma, and Entrada Therapeutics. He was previously a Board Observer with Homology Medicines (NASDAQ: FIXX). Previously he was a postdoctoral fellow in Levi Garraway’s laboratory at the Dana-Farber Cancer Institute and the Broad Institute of MIT and Harvard, where his work was published in Science. Before that, he was an HHMI-NIBIB Interfaces Scholar at the University of Pennsylvania, where he received his PhD in Bioengineering In Lewis Chodosh’s lab. He is passionate about maximizing the impact that the CDCN has on patients by identifying research areas that further understanding about Castleman Disease in a clinically meaningful way.